279 related articles for article (PubMed ID: 20800070)
1. Expression-system-dependent modulation of HIV-1 envelope glycoprotein antigenicity and immunogenicity.
Kong L; Sheppard NC; Stewart-Jones GBE; Robson CL; Chen H; Xu X; Krashias G; Bonomelli C; Scanlan CN; Kwong PD; Jeffs SA; Jones IM; Sattentau QJ
J Mol Biol; 2010 Oct; 403(1):131-147. PubMed ID: 20800070
[TBL] [Abstract][Full Text] [Related]
2. Hyperglycosylated stable core immunogens designed to present the CD4 binding site are preferentially recognized by broadly neutralizing antibodies.
Ingale J; Tran K; Kong L; Dey B; McKee K; Schief W; Kwong PD; Mascola JR; Wyatt RT
J Virol; 2014 Dec; 88(24):14002-16. PubMed ID: 25253346
[TBL] [Abstract][Full Text] [Related]
3. Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect Cells.
Urbanowicz RA; Wang R; Schiel JE; Keck ZY; Kerzic MC; Lau P; Rangarajan S; Garagusi KJ; Tan L; Guest JD; Ball JK; Pierce BG; Mariuzza RA; Foung SKH; Fuerst TR
J Virol; 2019 Apr; 93(7):. PubMed ID: 30651366
[TBL] [Abstract][Full Text] [Related]
4. Characterization of host-cell line specific glycosylation profiles of early transmitted/founder HIV-1 gp120 envelope proteins.
Go EP; Liao HX; Alam SM; Hua D; Haynes BF; Desaire H
J Proteome Res; 2013 Mar; 12(3):1223-34. PubMed ID: 23339644
[TBL] [Abstract][Full Text] [Related]
5. Cell- and Protein-Directed Glycosylation of Native Cleaved HIV-1 Envelope.
Pritchard LK; Harvey DJ; Bonomelli C; Crispin M; Doores KJ
J Virol; 2015 Sep; 89(17):8932-44. PubMed ID: 26085151
[TBL] [Abstract][Full Text] [Related]
6. Induction of HIV-1 envelope (gp120)-specific cytotoxic T lymphocyte responses in mice by recombinant CHO cell-derived gp120 is enhanced by enzymatic removal of N-linked glycans.
Doe B; Steimer KS; Walker CM
Eur J Immunol; 1994 Oct; 24(10):2369-76. PubMed ID: 7523139
[TBL] [Abstract][Full Text] [Related]
7. Comparative Analysis of the Glycosylation Profiles of Membrane-Anchored HIV-1 Envelope Glycoprotein Trimers and Soluble gp140.
Go EP; Herschhorn A; Gu C; Castillo-Menendez L; Zhang S; Mao Y; Chen H; Ding H; Wakefield JK; Hua D; Liao HX; Kappes JC; Sodroski J; Desaire H
J Virol; 2015 Aug; 89(16):8245-57. PubMed ID: 26018173
[TBL] [Abstract][Full Text] [Related]
8. Changes in Structure and Antigenicity of HIV-1 Env Trimers Resulting from Removal of a Conserved CD4 Binding Site-Proximal Glycan.
Liang Y; Guttman M; Williams JA; Verkerke H; Alvarado D; Hu SL; Lee KK
J Virol; 2016 Oct; 90(20):9224-36. PubMed ID: 27489265
[TBL] [Abstract][Full Text] [Related]
9. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
Roben P; Moore JP; Thali M; Sodroski J; Barbas CF; Burton DR
J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527
[TBL] [Abstract][Full Text] [Related]
10. Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens.
Doores KJ; Bonomelli C; Harvey DJ; Vasiljevic S; Dwek RA; Burton DR; Crispin M; Scanlan CN
Proc Natl Acad Sci U S A; 2010 Aug; 107(31):13800-5. PubMed ID: 20643940
[TBL] [Abstract][Full Text] [Related]
11. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.
Binley JM; Sanders RW; Clas B; Schuelke N; Master A; Guo Y; Kajumo F; Anselma DJ; Maddon PJ; Olson WC; Moore JP
J Virol; 2000 Jan; 74(2):627-43. PubMed ID: 10623724
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 Glycan Density Drives the Persistence of the Mannose Patch within an Infected Individual.
Coss KP; Vasiljevic S; Pritchard LK; Krumm SA; Glaze M; Madzorera S; Moore PL; Crispin M; Doores KJ
J Virol; 2016 Dec; 90(24):11132-11144. PubMed ID: 27707925
[TBL] [Abstract][Full Text] [Related]
13. Glycosylation of the core of the HIV-1 envelope subunit protein gp120 is not required for native trimer formation or viral infectivity.
Rathore U; Saha P; Kesavardhana S; Kumar AA; Datta R; Devanarayanan S; Das R; Mascola JR; Varadarajan R
J Biol Chem; 2017 Jun; 292(24):10197-10219. PubMed ID: 28446609
[TBL] [Abstract][Full Text] [Related]
14. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
[TBL] [Abstract][Full Text] [Related]
15. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.
Koch M; Pancera M; Kwong PD; Kolchinsky P; Grundner C; Wang L; Hendrickson WA; Sodroski J; Wyatt R
Virology; 2003 Sep; 313(2):387-400. PubMed ID: 12954207
[TBL] [Abstract][Full Text] [Related]
16. Isolate-specific differences in the conformational dynamics and antigenicity of HIV-1 gp120.
Davenport TM; Guttman M; Guo W; Cleveland B; Kahn M; Hu SL; Lee KK
J Virol; 2013 Oct; 87(19):10855-73. PubMed ID: 23903848
[TBL] [Abstract][Full Text] [Related]
17. Glycan Profiles of gp120 Protein Vaccines from Four Major HIV-1 Subtypes Produced from Different Host Cell Lines under Non-GMP or GMP Conditions.
Wang S; Voronin Y; Zhao P; Ishihara M; Mehta N; Porterfield M; Chen Y; Bartley C; Hu G; Han D; Wells L; Tiemeyer M; Lu S
J Virol; 2020 Mar; 94(7):. PubMed ID: 31941770
[TBL] [Abstract][Full Text] [Related]
18. Antibodies against Manalpha1,2-Manalpha1,2-Man oligosaccharide structures recognize envelope glycoproteins from HIV-1 and SIV strains.
Luallen RJ; Agrawal-Gamse C; Fu H; Smith DF; Doms RW; Geng Y
Glycobiology; 2010 Mar; 20(3):280-6. PubMed ID: 19920089
[TBL] [Abstract][Full Text] [Related]
19. Highly conserved HIV-1 gp120 glycans proximal to CD4-binding region affect viral infectivity and neutralizing antibody induction.
Huang X; Jin W; Hu K; Luo S; Du T; Griffin GE; Shattock RJ; Hu Q
Virology; 2012 Feb; 423(1):97-106. PubMed ID: 22192629
[TBL] [Abstract][Full Text] [Related]
20. Enhanced immunogenicity of a human immunodeficiency virus type 1 env DNA vaccine by manipulating N-glycosylation signals. Effects of elimination of the V3 N306 glycan.
Bolmstedt A; Hinkula J; Rowcliffe E; Biller M; Wahren B; Olofsson S
Vaccine; 2001 Nov; 20(3-4):397-405. PubMed ID: 11672902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
